autologous dntgf-brii-armored anti-steap2 car t-cells azd0754
autologous dntgf-brii-armored anti-steap2 car t-cells azd0754: 1 clinical trial tracked.
autologous dntgf-brii-armored anti-steap2 car t-cells azd0754 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
What is verified about autologous dntgf-brii-armored anti-steap2 car t-cells azd0754, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants With Metastatic Prostate Cancer: APOLLO
Primary endpoint: Incidence of participants with Dose-limiting Toxicity (DLTs)/DLT-like events, Adverse Events (AEs), including Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs).